As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner
This article was originally published in PharmAsia News
Executive Summary
The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.